(Date:5/9/2008)...RNewswire-FirstCall/ -- Sunrise Senior Living,Inc...chief investment and,administrative officer, will ...ference in Las Vegas on Wednesday, May 14, 2008 at...the presentation live on the Investor Relations,se...niorliving.com ). A,replay of the Web cast will be...
(Date:5/9/2008)...May 9 /PRNewswire/ -- SheKnows.com,( http://www.Sh...roperties,for women online announced Lisa Stevenso... by an overwhelming vote from online community rea...nh/20080509/LAF049 ), Stevenson lives in Alaska f...al coal strip mine infiltration. "We,re trying to ...
(Date:5/9/2008)...ts at Washington University School of Medicine in ... in unprecedented detail the immune cells long tho...esearchers were able to examine the immune cells f...reas known as the islets of Langerhans. They caugh...-handed": carrying insulin and fragments of insuli...
(Date:5/9/2008)...RNewswire-FirstCall/ -- Somanetics Corporation,(Na...rectors has authorized,the Company to repurchase u...s (for a total of $30 million of its common shares...open market or in privately negotiated,transaction...for, any,purchases will be determined by the Compa...
Breaking Medicine News(10 mins):Health News:SheKnows Names America's Most Extreme Mom for Mother's Day 2Health News:Suspected cause of type 1 diabetes caught 'red-handed' for the first time 2Health News:Suspected cause of type 1 diabetes caught 'red-handed' for the first time 3Health News:Somanetics Announces Share Repurchase Program Increased by $15 Million 2...est to determine the genetical predisposition for ...Malignant hyperthermia is an inherited disorder th...anesthesia. This condition may be triggered by vol...le relaxants that have to work together with a gen...
...isease tetanus, have therapeutic properties that c...xiety disorder, depression and anorexia. Researche...in have discovered the beneficial effects of the t...art of the toxin called the carboxy-terminal domai...
...that are worn during long hours of flying can sign...s. Researchers of the study had compared nine stud...istance in airlines. The researchers had carried o... all the participants of the study to walk or exer...
...rence diabetic retinopathy in a number of people//... Diabetes type 2 happens when body cannot use its ...s the body becomes unable to produce enough insuli...eep up to the need of the body. Pre-diabetes condi...
Other Medicine News:(Date:5/8/2008)...er Research Alliance, an,organization comprised of...303 million Americans to exercise their power over...this Mother,s Day through Father,s Day., The camp...wo key goals:,to activate Americans everywhere to ...her to exercise their collective power over cancer...
(Date:5/8/2008)...ll/ -- Alpharma Inc. (NYSE: ALO ),a global speci...ts from,clinical trials that showed ALO-01 (EMBEDA...estered naltrexone hydrochloride) capsules,demonst...e liability,alongside a promising safety and effic... at the 27th Annual Scientific Session of the Amer...
(Date:5/8/2008)...rstCall/ -- VION PHARMACEUTICALS,INC. (Nasdaq: V...-sponsored,Phase I/II clinical trial of its lead a...ination with cytarabine in elderly patients with,p...L) and high-risk,myelodysplastic syndromes (MDS). ...f Ellen K. Ritchie, M.D. at The Weill-Cornell Medi...
(Date:5/8/2008)... Investigators to Assess BSI-201 Therapy...BANE, Calif., May 8 /- BiPar Sciences...inical trial programs for its lead,product, BSI-20...ical trial,of BSI-201 that BiPar has launched in t...breast and brain cancer., The company is evaluati...
Breaking Medicine Technology:World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 3Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 4Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 6Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 7Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2High Performing Healthcare Organizations Have Seven Qualities in Common 15040 1High Performing Healthcare Organizations Have Seven Qualities in Common 15040 2High Performing Healthcare Organizations Have Seven Qualities in Common 15040 3Varian Medical Systems Schedules Second Quarter FY2008 News Release and Conference Call 4168 1Varian Medical Systems Schedules Second Quarter FY2008 News Release and Conference Call 4168 2Varian Medical Systems Schedules Second Quarter FY2008 News Release and Conference Call 4168 3Neighborhood Influences Exercise Levels 15036 1Neighborhood Influences Exercise Levels 15036 2Giving Children Hope to Hold Onto 15034 1Giving Children Hope to Hold Onto 15034 2Giving Children Hope to Hold Onto 15034 3...May 10, 2007 - GenVec, Inc.,(Nasdaq:GNVC) today an...ility of the Company,s new adenovector, Ad35, to i...isa L. Wei, Ph.D., GenVec,s,Director of Pre-Clinic...e Adenovector Gives Long-Term Expression in the Ey...phthalmology ("ARVO"),Annual Meeting in Fort Laude...
...May 14, 2007 - BioDelivery,Sciences International,...cally significant results with BEMA Fentanyl in ca...III efficacy clinical,trial for the product., Resu...s of the,secondary efficacy endpoints from the stu...ary of Pain Intensity Difference at,15 minutes), a...
Other Medicine Technology:GenVec Presents Research on New Ad35 Adenovector at ARVO 2GenVec Presents Research on New Ad35 Adenovector at ARVO 3BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 2BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 3BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 4Compact networked patient monitors for flexible care.
...patient monitoring, IntelliVue has highly flexible...rements menu; built-in clinical support tools such... and arrhythmia analysis; and many other powerful ...s on a networked platform that can span the hospit...
Generra Narkotron II is a comprehensive vital sign monitor. , ,Adult, pediatric, and neonatal. , ,Providing high quality, affordable products for efficiency in patient care., ,Standard Functions:
...ow-cost, multi-parameter monitor designed specific...res, and surgery. The large display provides brigh... across the room. The intuitive design allows user...tes., ,Standard features include 3-lead or 5-lead...
Medicine Products: